Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07352566 · ClinicalTrials.gov registry record · Phase 4
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
A Phase 4 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT07352566: Clinical Trial Phase 4 study, sponsored by University of California, San Francisco.
NCT07352566 is a Phase 4 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07352566, a Phase 4 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Primary Outcome
The safety of microdevice placement and removal will be based on assessment of adverse events.
Interventions
- DRUG 5-Fluorouracil
- DRUG Tapinarof
- DRUG Calcipotriene
- DRUG Triamcinolone
- DEVICE In situ cutaneous microdevice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-06-01 |
| Phase | Phase 4 |
What is known before NCT07352566 opens enrollment
NCT07352566 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which 5-Fluorouracil is the first listed.
NCT07352566 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07352566 about?
NCT07352566 is a clinical study titled "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis". This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the ...
What is the current status of trial NCT07352566?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2026-08-01. Estimated completion is 2030-06-01.
What interventions are being tested in trial NCT07352566?
The interventions under investigation include: 5-Fluorouracil (DRUG), Tapinarof (DRUG), Calcipotriene (DRUG), Triamcinolone (DRUG), In situ cutaneous microdevice (DEVICE).
Who is sponsoring clinical trial NCT07352566?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07352566's enrollment target sits among peer trials
10 1940th of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI